Next Article in Journal
Spirothiazolidine-Derivative on Silver Nanoparticles and Carbon Nanotubes: Evaluation of Antibacterial, Anti-Fungal, Anti-Inflammatory, Antioxidant and Gastroprotective Activities
Previous Article in Journal
Enhanced Cytotoxicity against a Pancreatic Cancer Cell Line Combining Radiation and Gold Nanoparticles
Previous Article in Special Issue
Development, Characterization, and Evaluation of Potential Systemic Toxicity of a Novel Oral Melatonin Formulation
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
This is an early access version, the complete PDF, HTML, and XML versions will be available soon.
Article

Enrofloxacin Pharmaceutical Formulations through the Polymer-Free Electrospinning of β-Cyclodextrin–oligolactide Derivatives

by
Diana-Andreea Blaj
1,2,
Cătălina Anișoara Peptu
2,
Maricel Danu
2,
Valeria Harabagiu
1,
Cristian Peptu
1,*,
Alexandra Bujor
3,
Lăcrămioara Ochiuz
3,* and
Cristina Gabriela Tuchiluș
4
1
“Petru Poni” Institute of Macromolecular Chemistry, 700487 Iasi, Romania
2
Faculty of Chemical Engineering and Protection of the Environment, “Gheorghe Asachi” Technical University of Iasi, 700050 Iasi, Romania
3
Faculty of Pharmacy, “Grigore. T. Popa” University of Medicine and Pharmacy, 700115 Iasi, Romania
4
Faculty of Medicine, “Grigore. T. Popa” University of Medicine and Pharmacy, 700115 Iasi, Romania
*
Authors to whom correspondence should be addressed.
Pharmaceutics 2024, 16(7), 903; https://doi.org/10.3390/pharmaceutics16070903 (registering DOI)
Submission received: 31 May 2024 / Revised: 28 June 2024 / Accepted: 4 July 2024 / Published: 5 July 2024
(This article belongs to the Special Issue Advances in Polymeric Drug Delivery Systems, 2nd Edition)

Abstract

Enrofloxacin (ENR), a member of the fluoroquinolone class of antibiotics, is widely used in veterinary medicine to treat bacterial infections. Like many antibiotics, ENR has limited water solubility and low bioavailability. To address these challenges, drug formulations using solid dispersions, nanosuspensions, surfactants, cocrystal/salt formation, and inclusion complexes with cyclodextrins may be employed. The approach described herein proposes the development of ENR formulations by co-electrospinning ENR with custom-prepared cyclodextrin–oligolactide (CDLA) derivatives. This method benefits from the high solubility of these derivatives, enabling polymer-free electrospinning. The electrospinning parameters were optimized to incorporate significant amounts of ENR into the CDLA nanofibrous webs, reaching up to 15.6% by weight. The obtained formulations were characterized by FTIR and NMR spectroscopy methods and evaluated for their antibacterial activity against Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa. This study indicates that the presence of CDLA derivative does not inhibit the antibacterial activity of ENR, recommending these formulations for further development.
Keywords: enrofloxacin; cyclodextrin–oligolactide; electrospinning; antibacterial activity; nanofibers enrofloxacin; cyclodextrin–oligolactide; electrospinning; antibacterial activity; nanofibers

Share and Cite

MDPI and ACS Style

Blaj, D.-A.; Peptu, C.A.; Danu, M.; Harabagiu, V.; Peptu, C.; Bujor, A.; Ochiuz, L.; Tuchiluș, C.G. Enrofloxacin Pharmaceutical Formulations through the Polymer-Free Electrospinning of β-Cyclodextrin–oligolactide Derivatives. Pharmaceutics 2024, 16, 903. https://doi.org/10.3390/pharmaceutics16070903

AMA Style

Blaj D-A, Peptu CA, Danu M, Harabagiu V, Peptu C, Bujor A, Ochiuz L, Tuchiluș CG. Enrofloxacin Pharmaceutical Formulations through the Polymer-Free Electrospinning of β-Cyclodextrin–oligolactide Derivatives. Pharmaceutics. 2024; 16(7):903. https://doi.org/10.3390/pharmaceutics16070903

Chicago/Turabian Style

Blaj, Diana-Andreea, Cătălina Anișoara Peptu, Maricel Danu, Valeria Harabagiu, Cristian Peptu, Alexandra Bujor, Lăcrămioara Ochiuz, and Cristina Gabriela Tuchiluș. 2024. "Enrofloxacin Pharmaceutical Formulations through the Polymer-Free Electrospinning of β-Cyclodextrin–oligolactide Derivatives" Pharmaceutics 16, no. 7: 903. https://doi.org/10.3390/pharmaceutics16070903

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop